Value analysis of CD69 combined with EGR1 in the diagnosis of coronary heart disease

Peng,Jianqiao; Xiang,Yi

doi:10.3892/etm.2019.7175

Value analysis of CD69 combined with EGR1 in the diagnosis of coronary heart disease

Authors:
- Jianqiao Peng
- Yi Xiang
View Affiliations

Affiliations: Clinical Laboratory, People's Hospital of Hunan Province, Changsha, Hunan 410006, P.R. China, Department of Geriatrics, People's Hospital of Hunan Province, Changsha, Hunan 410006, P.R. China
Published online on: January 15, 2019 https://doi.org/10.3892/etm.2019.7175
Pages: 2047-2052
Copyright: © Peng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Expression and clinical significance of CD69 and early growth response (EGR1) in plasma of patients with coronary heart disease (CHD) were investigated. A total of 194 patients with CHD and 130 healthy subjects, respectively, were selected as CHD and control group, clinical data were collected and coronary angiography was performed. RT-qPCR was used to detect the expression of EGR1. Flow cytometry was used to detect the expression level of CD69 and the receiver operating characteristic curve was used to analyze the values of relative expression of CD69 and EGR1. The relative expression of CD69 in plasma of patients with CHD was higher than that in control group, while the relative expression of EGR1 was lower than that in control group. The relative expression of EGR1 in plasma of patients with CHD was negatively correlated with lipoprotein a [Lp(a)] and high sensitive C-reactive protein (hs-CRP) (r=-0.394 and -0.524, P<0.05), and the relative expression of CD69 in peripheral blood was positively correlated with [Lp(a)] and hs-CRP (r=0.352 and 0.402, P<0.05). The area under curve (AUC) of the relative expression of CD69 in peripheral blood of patients with CHD in evaluating the course of the disease of patients was 0.889 (95% CI: 0.822‑0.958). The AUC of the relative expression of EGR1 in plasma in evaluating the course of the disease of patients was 0.933 (95% CI: 0.867-0.978). By the combined detection of CD69 and EGR1, it was found that the AUC was 0.954 (95% CI: 0.887‑0.982). The expression level of EGR1 in plasma of patients with CHD decreased, while the expression level of CD69 increased, and both of them were related to the severity of the disease of patients, which could be used as an indicator to evaluate the progression of the patients' conditions.

View Figures

View References

1	García de Tena J: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 353:429–430; author reply 429–430. 2005. View Article : Google Scholar
2	Anderson L, Oldridge N, Thompson DR, Zwisler AD, Rees K, Martin N and Taylor RS: Exercise-based cardiac rehabilitation for coronary heart disease: Cochrane systematic review and meta-analysis. J Am Coll Cardiol. 67:1–12. 2016. View Article : Google Scholar : PubMed/NCBI
3	Catapano AL, Chapman J, Wiklund O and Taskinen MR: The new joint EAS/ESC guidelines for the management of dyslipidaemias. Atherosclerosis. 217:1–44. 2011. View Article : Google Scholar : PubMed/NCBI
4	Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, et al American Heart Association Statistics Committee and Stroke Statistics Subcommittee, : Heart disease and stroke statistics - 2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 119:e21–e181. 2009.PubMed/NCBI
5	Chen BJ, Pan ZQ and Su XX: Study on changes of TCM syndrome in patients with coronary heart disease before and after intervention treatment. Zhongguo Zhong Xi Yi Jie He Za Zhi. 27:689–691. 2007.(In Chinese). PubMed/NCBI
6	Pogosova N, Kotseva K, De Bacquer D, von Känel R, De Smedt D, Bruthans J and Dolzhenko M: EUROASPIRE Investigators: Psychosocial risk factors in relation to other cardiovascular risk factors in coronary heart disease: Results from the EUROASPIRE IV survey. A registry from the European Society of Cardiology. Eur J Prev Cardiol. 24:1371–1380. 2017. View Article : Google Scholar : PubMed/NCBI
7	Mackay LK, Rahimpour A, Ma JZ, Collins N, Stock AT, Hafon ML, Vega-Ramos J, Lauzurica P, Mueller SN, Stefanovic T, et al: The developmental pathway for CD103⁺CD8⁺ tissue-resident memory T cells of skin. Nat Immunol. 14:1294–1301. 2013. View Article : Google Scholar : PubMed/NCBI
8	Marsolais D, Yagi S and Rosen H: Activation of sphingosine-1-phosphate receptor 1 inhibits CD4⁺ T cell response in a murine model of allergic airway inflammation. Am J Respir Crit Care Med. 179:A43042009.
9	Kumar SS, Tomita Y, Wrin J, Bruhn M, Swalling A, Mohammed M, Price TJ and Hardingham JE: High early growth response 1 (EGR1) expression correlates with resistance to anti-EGFR treatment in vitro and with poorer outcome in metastatic colorectal cancer patients treated with cetuximab. Clin Transl Oncol. 19:718–726. 2017. View Article : Google Scholar : PubMed/NCBI
10	Bhattacharyya S, Wu M, Fang F, Tourtellotte W, Feghali-Bostwick C and Varga J: Early growth response transcription factors: Key mediators of fibrosis and novel targets for anti-fibrotic therapy. Matrix Biol. 30:235–242. 2011. View Article : Google Scholar : PubMed/NCBI
11	Sun M, Nie FQ, Zang C, Wang Y, Hou J, Wei C, Li W, He X and Lu KH: The pseudogene DUXAP8 promotes non-small-cell lung cancer cell proliferation and invasion by epigenetically silencing EGR1 and RHOB. Mol Ther. 25:739–751. 2017. View Article : Google Scholar : PubMed/NCBI
12	Dang Y, Luo D and Rong M: Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET. PloS one. 8:e610542013. View Article : Google Scholar : PubMed/NCBI
13	Satija A, Bhupathiraju SN, Spiegelman D, Chiuve SE, Manson JE, Willett W, Rexrode KM, Rimm EB and Hu FB: Healthful and unhealthful plant-based diets and the risk of coronary heart disease in U.S. adults. J Am Coll Cardiol. 70:411–422. 2017. View Article : Google Scholar : PubMed/NCBI
14	Blechacz B: Cholangiocarcinoma: Current knowledge and new developments. Gut Liver. 11:13–26. 2017. View Article : Google Scholar : PubMed/NCBI
15	Zhou M, Wang H, Zhu J, Chen W, Wang L, Liu S, Li Y, Wang L, Liu Y, Yin P, et al: Cause-specific mortality for 240 causes in China during 1990–2013: A systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet. 387:251–272. 2016. View Article : Google Scholar : PubMed/NCBI
16	Danad I, Szymonifka J, Twisk JWR, Norgaard BL, Zarins CK, Knaapen P and Min JK: Diagnostic performance of cardiac imaging methods to diagnose ischaemia-causing coronary artery disease when directly compared with fractional flow reserve as a reference standard: A meta-analysis. Eur Heart J. 38:991–998. 2017.PubMed/NCBI
17	Kimura MY, Hayashizaki K, Tokoyoda K, Takamura S, Motohashi S and Nakayama T: Crucial role for CD69 in allergic inflammatory responses: CD69-Myl9 system in the pathogenesis of airway inflammation. Immunol Rev. 278:87–100. 2017. View Article : Google Scholar : PubMed/NCBI
18	Hayashi Y, Okutani M, Ogawa S, Tsukahara T and Inoue R: Generation of anti-porcine CD69 monoclonal antibodies and their usefulness to evaluate early activation of cellular immunity by flow cytometric analysis. Anim Sci J 2018. Anim Sci J. 89:825–832. 2018. View Article : Google Scholar : PubMed/NCBI
19	Lei L, Cui L, Mao Y, Zhang X, Jiang Q, Dong S and Wang Y: Augmented CD25 and CD69 expression on circulating CD8⁺ T cells in type 2 diabetes mellitus with albuminuria. Diabetes Metab. 43:382–384. 2017. View Article : Google Scholar : PubMed/NCBI
20	Ghatak S, Markwald RR, Hascall VC, Dowling W, Lottes RG, Baatz JE, Beeson G, Beeson CC, Perrella MA, Thannickal VJ, et al: Transforming growth factor β1 (TGFβ1) regulates CD44V6 expression and activity through extracellular signal-regulated kinase (ERK)-induced EGR1 in pulmonary fibrogenic fibroblasts. J Biol Chem. 292:10465–10489. 2017. View Article : Google Scholar : PubMed/NCBI
21	Shajahan-Haq AN, Boca SM, Jin L, Bhuvaneshwar K, Gusev Y, Cheema AK, Demas DD, Raghavan KS, Michalek R, Madhavan S, et al: EGR1 regulates cellular metabolism and survival in endocrine resistant breast cancer. Oncotarget. 8:96865–96884. 2017. View Article : Google Scholar : PubMed/NCBI
22	Xu S, Bendeck M and Gotlieb AI: Vascular pathobiology: Atherosclerosis and large vessel disease. Cardiovascular Pathology. Butany J and Buja M: 4th. Academic Press; MA: pp. 85–124. 2016, View Article : Google Scholar
23	Toutouzas K, Colombo A and Stefanadis C: Inflammation and restenosis after percutaneous coronary interventions. Europ Heart J. 25:1679–1687. 2004. View Article : Google Scholar
24	Vogt A: Hyperlipoproteinaemia(a) - apheresis and emerging therapies. Clin Res Cardiol Suppl. 12 Suppl 1:12–17. 2017. View Article : Google Scholar : PubMed/NCBI
25	Tayefi M, Tajfard M, Saffar S, Hanachi P, Amirabadizadeh AR, Esmaeily H, Taghipour A, Ferns GA, Moohebati M and Ghayour-Mobarhan M: hs-CRP is strongly associated with coronary heart disease (CHD): A data mining approach using decision tree algorithm. Comput Methods Programs Biomed. 141:105–109. 2017. View Article : Google Scholar : PubMed/NCBI